TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05035823

Intervention type: DEVICE
Group type: OTHER
Intervention: Motor Neuroprosthesis (MNP)
Description: Type of implantable brain computer interface
Study: NCT04702048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection
Description: Patients randomized to Arm A will receive 2 mg IVT aflibercept injections every 4 weeks (Q4W) to Week 20, followed by 2-mg aflibercept injections Q8W to Week 52.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sham injection
Description: Patients randomized to Arm B will receive sham intravitreal injections every 4 weeks (Q4W) to Week 20, followed by sham intravitreal injections Q8W to Week 52. Sham means eye will be numbed and a syringe with no needle will be touched to the eye.
Study: NCT05052528

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chimeric Antigen Receptor T-Cell Therapy
Description: Given CD19 CAR T cells IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chimeric Antigen Receptor T-Cell Therapy
Description: Given CD19 CAR T cells IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chimeric Antigen Receptor T-Cell Therapy
Description: Given CD19 CAR T cells IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chimeric Antigen Receptor T-Cell Therapy
Description: Given CD19 CAR T cells IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chimeric Antigen Receptor T-Cell Therapy
Description: Given CD19 CAR T cells IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chimeric Antigen Receptor T-Cell Therapy
Description: Given CD19 CAR T cells IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT05077436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamifeport Formulation 2
Description: Vamifeport Formulation 2 is available as 60 mg oral capsules
Study: NCT05161650

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone monoester (3-OHB)
Description: Commercially available ketone supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo drink
Description: Isocaloric placebo
Study: NCT05114837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allogeneic CAR19 regulatory T cells (CAR19-tTreg)
Description: A single dose administration of CAR19-tTreg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 30 mg/m\^2 is administered as an intravenous (IV) infusion per institutional guidelines once a day on 4 consecutive days (Day -5, Day -4, Day -3 and Day -2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 500 mg/m\^2 is administered as an IV infusion per institutional guidelines once a day on 2 consecutive days (Day -5, and Day -4)
Study: NCT05596721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Treat patient with azithromycin for 12w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICS/LABA
Description: Treat patient with ICS/LABA according to Global Initiative for Asthma (GINA) guideline.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ICS/LABA
Description: Treat patient with ICS/LABA according to Global Initiative for Asthma (GINA) guideline.
Study: NCT05369286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAX-40279-01 and Toripalimab
Description: MAX-40279-01combined with Toripalimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAX-40279-01 and Toripalimab
Description: MAX-40279-01combined with Toripalimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAX-40279-01 and Toripalimab
Description: MAX-40279-01combined with Toripalimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAX-40279-01 and Toripalimab
Description: MAX-40279-01combined with Toripalimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAX-40279-01 and Toripalimab
Description: MAX-40279-01combined with Toripalimab
Study: NCT06397820

Intervention type: DEVICE
Intervention: Percutaneous coronary intervention (PCI)
Description: Revascularization by percutaneous coronary intervention for vessels with decreased PET-derived flow indexes
Study: NCT05886439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LK101 injection (personlized neoantigen pulsed DC vaccine )
Description: LK101 will be administered in a prime-boost schedule of 4 priming vaccination followed by 3 booster vaccinations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LK101 injection (personlized neoantigen pulsed DC vaccine )
Description: LK101 will be administered in a prime-boost schedule of 4 priming vaccination followed by 3 booster vaccinations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients will receive pembrolizumab(200mg IV) Q3W until disease progression (PD), intolerable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Patients will receive durvalumab (1500mg IV) Q3W until disease progression (PD), intolerable toxicity.
Study: NCT04802707

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: deoxycytidine and deoxythymidine
Description: The Investigational Product (IP) dC/dT100-400 will be administered orally every day (QD) and the dose is divided over 3 taking/day for the daily dose of 100 mg/kg from Day 1-7, 200 mg/kg from Day 8-14, 300 mg/kg from Day 15- 21 and 400 mg/kg from Day 22 to 730. Doses was chosen according to the safety and efficacy doses used in the literature.
Study: NCT05415774

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1 : S-C1-C2
Description: Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1 : S-C1-C2
Description: Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1 : S-C1-C2
Description: Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2 : S-C2-C1
Description: Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2 : S-C2-C1
Description: Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2 : S-C2-C1
Description: Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3 : C1 - S - C2
Description: Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3 : C1 - S - C2
Description: Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2
Study: NCT05052528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT05076292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GlucaGen
Description: 150 ug or 75\*2 ug glucagon will be administered subcutaneously to the participants before and after exercise.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GlucaGen
Description: 150 ug or 75\*2 ug glucagon will be administered subcutaneously to the participants before and after exercise.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Saline will be used as placebo before and after exercise.
Study: NCT05415774

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3 : C1 - S - C2
Description: Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4 : C1 -C2 - S
Description: Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2
Study: NCT04456946

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy
Description: Low Level Laser Therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occlusal Splint Treatment
Description: Occlusal Splint Treatment
Study: NCT06557746

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coca-Cola
Description: 100 ml Coca-Cola every 30 minutes during the operation
Study: NCT05415774

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4 : C1 -C2 - S
Description: Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2
Study: NCT06557746

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen
Description: Continuous supply of oxygen (2 L/min) during the operation
Study: NCT05415774

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 4 : C1 -C2 - S
Description: Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2
Study: NCT05052528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study: NCT05415774

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5 : C2 - S - C1
Description: Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5 : C2 - S - C1
Description: Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 5 : C2 - S - C1
Description: Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 6 : C2 - C1 - S
Description: Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 6 : C2 - C1 - S
Description: Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 6 : C2 - C1 - S
Description: Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2
Study: NCT05052528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study: NCT04954534

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human umbilical cord blood derived mesenchymal stem cells
Description: High dose: 3 x 10\^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4-week intervals
Study: NCT05065593

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resistance and aerobic exercise
Description: Resistive exercises allow loading the muscle under suitable conditions with various weights or resistances. In order to increase the level of physical fitness with the increase of muscle strength and bone mass in individuals, resistance exercises were preferred. Aerobic exercises, on the other hand, are a special type of exercise that develops both the musculoskeletal system and the cardiovascular system, which includes large muscle groups and should be performed for at least 20 minutes when the heart rate accelerates at certain rates. Aerobic exercise was preferred in order to increase cardiovascular endurance, accelerate fat burning and reduce fatigue.
Study: NCT05052528

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study: NCT05065593

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical activity recommendation
Description: Patients will be informed about the importance of lifestyle change in disease management, walking training will be given to increase their physical activity level, and participants will be asked to follow a 45-minute walking program every day within their own means.
Study: NCT06179680

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: MRI Protocol: Uses advanced MRI sequences to examine brain structures and detect white matter issues.~WMH Assessment: Evaluates white matter health using various methods, including manual and automated tools.~Neuropsychological Testing: Subjects undergo comprehensive cognitive testing administered by IRCCS Policlinico San Donato's Clinical Psychology Service.~Follow-up: Patients are monitored for cognitive changes semiannually, with additional assessments for those showing signs of progression. After two years, all patients undergo examination and tests to assess their condition.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: MRI Protocol: Uses advanced MRI sequences to examine brain structures and detect white matter issues.~WMH Assessment: Evaluates white matter health using various methods, including manual and automated tools.~Neuropsychological Testing: Subjects undergo comprehensive cognitive testing administered by IRCCS Policlinico San Donato's Clinical Psychology Service.~Follow-up: Patients are monitored for cognitive changes semiannually, with additional assessments for those showing signs of progression. After two years, all patients undergo examination and tests to assess their condition.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: MRI Protocol: Uses advanced MRI sequences to examine brain structures and detect white matter issues.~WMH Assessment: Evaluates white matter health using various methods, including manual and automated tools.~Neuropsychological Testing: Subjects undergo comprehensive cognitive testing administered by IRCCS Policlinico San Donato's Clinical Psychology Service.~Follow-up: Patients are monitored for cognitive changes semiannually, with additional assessments for those showing signs of progression. After two years, all patients undergo examination and tests to assess their condition.
Study: NCT05575622

Intervention type: DEVICE
Intervention: CTC PD-L1, exosomal PD-L1, and exosomal LAG-3 detection
Description: Collect peripheral blood sample of 200 HCC patients at treatment baseline, every time point response till disease progression.Blood samples will be transferred to central lab to detect CTC PD-L1, exosomal PD-L1, and exosomal LAG-3 by microfluidic chip.Tumor response evaluation will be performed after two cycles of therapy by CT/MRI based on RECIST.Clinical data, including tumor stage,metastatic organ ,regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.
Study: NCT05221281

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal intervention consisting of four core components
Description: Core Component 1: Individualized Assessment: Each participant will undergo individualized assessment of their biopsychosocial risk profile (PIBD INTERMED), self-efficacy (IBD-SES-A), function (IBD-DI), transition readiness (TRAQ) and IBD knowledge (IBD-KID2), and depression, anxiety and activation.~Core Component 2: Transition Navigator: Participants will be assigned a transition navigators, who will have knowledge of IBD, an understanding of the care pathway involved in transitioning IBD patients, and the skills and ability to provide psychosocial support.~Core Component 3: Participant Skills-building: Skills-building materials delivered virtually. Navigators will also be trained as motivational coaches and will lead separate personalized virtual sessions targeting individual skills that have been identified as deficient during the assessment phase.~Core Component 4: eLearning Curriculum: Organized online eLearning modules with reinforcement of knowledge by the navigators.
Study: NCT05733520

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain CareNotes
Description: The Brain CareNotes mobile telehealth app is used by unpaid caregivers for BPSD management. It includes remote communication with an external human support person-a care coach-as well as features for users to independently perform health-related activities.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dementia Guide Expert
Description: Dementia Guide Expert provides education only and no interactive BPSD management support, coaching, assessment, or external response. It contains evidence-based expert information on what dementia is, types, contributing factors, risks, symptoms, stages, diagnosis, tests, treatment, management, communication techniques, and links to resources and support services.
Study: NCT05221281

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard of care
Description: The control group will be provided a standardized version of routine care for transition. In addition to recruiting centers' standard of care, all participating centers will implement the following transition interventions:~1. A written letter explaining the goals of transition to the patient and family.~2. Completion of age-appropriate checklists to ensure adolescents are meeting milestones of transition (developed by the TRACC Network).51~3. Annual online live educational webinars on transition and adolescent issues (hosted by the CIDsCaNN Education Committee).~4. Completion of the Pediatric INTERMED,52 with appropriate biopsychosocial intervention.~5. Completion of a transfer-of-care summary letter sent to the receiving adult gastroenterologist using a standardized letter template.53~The Control Group may also receive any interventions currently in place in their participating care center, but will not receive the formal 4-component intervention described below.
Study: NCT05183295

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NEAAR Medical Food
Description: Standardized non-essential amino acid restricted medical food
Study: NCT06395376

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bikram Hot Yoga Intervention
Description: Active participants engage in a yoga intervention which entails participating in a minimum of 60-minutes of hot yoga (Bikram sequence), 3x per week in a heated room at 40 degrees C. The intervention will be 6-weeks of active intervention when they are participating in yoga, followed by an 6-week washout period where they will be asked to not practice yoga. Participants will be asked to give blood at 9 timepoints throughout the 12-week study, including baseline, week one, midpoint, end of Hot Yoga Intervention (Week 6) and after Washout (Week 12)

Intervention type: OTHER
Group type: OTHER
Intervention: Hot Yoga Washout
Description: The Washout period consists of 6-weeks occurring immediately after the Hot Yoga Intervention during which the participants do not perform any hot yoga.
Study: NCT06534528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human umbilical cord mesenchymal stem cell injection
Description: Different doses of human umbilical cord mesenchymal stem cell injection were infused to the focus of patients with idiopathic pulmonary fibrosis through bronchoscope, and the tolerance of subjects to different doses of human umbilical cord mesenchymal stem cell injection was observed, and the curative effect was preliminarily observed.